Immunotherapies for cancer and infectious diseases
Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biotechnology company focused on discovering and developing immune-targeted therapies for the treatment of cancer and infectious diseases.
Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biotechnology company focused on discovering and developing immune-targeted therapies for the treatment of cancer and infectious diseases.
Latest News
- September 21, 2017 - Transgene Launches Invir.IO TM, its Integrated Platform for the Next Generation of Multifunctional Oncolytic Viruses
- September 19, 2017 - First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
- September 13, 2017 - First half-year 2017 in line with our objectives: All clinical programs progressing and new collaboration agreements signed
- September 11, 2017 - Transgene Receives FDA IND Approval to Begin a Clinical Trial with TG4010 + Nivolumab + Chemotherapy in the First-Line Treatment of Lung Cancer (NSCLC)
